PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Chen, Chang Long ^a   Pan, Qiu Zhong ^a   Zhao, Jing Jing ^a   Wang, Ying ^b   Li, Yong Qiang ^a   Wang, Qi Jing ^a   Pan, Ke ^a   Weng, De Sheng ^a   Jiang, Shan Shan ^a   Tang, Yan ^a   Zhang, Xiao Fei ^a   Zhang, Hong Xia ^a   Zhou, Zi Qi ^a   Zeng, Yi Xin ^a   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Adjuvant CIK immunotherapy; hepatocellular carcinoma; immunohistochemistry; PD L1; survival benefit

Indexed keywords

CELL THERAPY AGENT; CYTOKINE; PD L1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHILL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE INDUCED KILLER CELL; DEMOGRAPHY; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYALGIA; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; VIRUS LOAD; VOMITING;

EID: 84976402721     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1176653     Document Type: Article

References (48)

1. J.J.Knox, S.P.Cleary, L.A.Dawson. Localized and Systemic Approaches to Treating Hepatocellular Carcinoma. J Clin Oncol 2015; 33:1835-44; PMID:25918289; http://dx.doi.org/10.1200/JCO.2014.60.1153
2. F.Alejandro, M.L.Josep, B.Jordi. Hepatocellular Carcinoma. Lancet 2012; 379:1245-55; PMID:22353262; http://dx.doi.org/10.1016/S0140-6736(11)61347-0
3. F.Jacques, S.Hai-Rim, B.Freddie, F.David, M.Colin, M.P.Donald. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
4. S.V.Ulahannan A.G.Duffy, T.S.McNeel, J.K.Kish, L.A.Dickie, O.E.Rahma, K.A.McGlynn T.F.Greten, S.F.Altekruse. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatol 2014; 60:1637-44; PMID:24996116; http://dx.doi.org/10.1002/hep.27288
5. J.M.Llovet, S.Ricci, V.Mazzaferro, P.Hilgard, E.Gane, J.F.Blanc, A.C.de Oliveira, A.Santoro, J.L.Raoul, A.Forner et al. Sorafenib in Advanced Hepatocellular. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
6. B.Hashem, S.El-Serag. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27; PMID:21992124; http://dx.doi.org/10.1056/NEJMra1001683
7. A.C.Ochoa, G.Gromo, B.J.Alter, P.M.Sondel, F.H.Bach Long-term growth of lymphokine-activated killer (LAK) cells:role of anti-CD3, β-IL 1, interferon-gamma and -β. J Immunol 1987; 138:2728-273; PMID:2435804
8. M.R.Verneris, M.Ito., J.Baker, A.Arshi, R.S.Negrin, J.A.Shizuru. Engineering hematopoietic grafts:purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001; 7:532-42; PMID:11760085; http://dx.doi.org/10.1016/S1083-8791(01)70014-6
9. J.S.Kim, Y.G.Kim, M.Pyo, H.K.Lee, J.T.Hong, Y.Kim, S.B.Han. Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. Immune Netw 2015; 15:58-65; PMID:25922594; http://dx.doi.org/10.4110/in.2015.15.2.58
10. T.Takayama, T.Sekine, M.Makuuchi, S.Yamasaki, T.Kosuge, J.Yamamoto, K.Shimada, M.Sakamoto, S.Hirohashi, Y.Ohashi et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial. Lancet 2000; 356:802-807; PMID:11022927; http://dx.doi.org/10.1016/S0140-6736(00)02654-4
11. D.Hui, L.Qiang, W.Jian, Z.Ti, K.Da-Lu. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009; 41:36-41; PMID:18818130; http://dx.doi.org/10.1016/j.dld.2008.04.007
12. K.Pan, Y.Q.Li, W.Wang, L.Xu, Y.J.Zhang, H.X.Zheng, J.J.Zhao, H.J.Qiu, D.S.Weng, J.J.Li et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 2013; 20:4305-11; PMID:23892527; http://dx.doi.org/10.1245/s10434-013-3144-x
13. J.H.Lee, Y.S.Lim, J.E.Yeon, T.J.Song, S.J.Yu, G.Y.Gwak, K.M.Kim, Y.J.Kim, J.W.Lee, J.H.Yoon. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148:1383-1391; PMID:25747273; http://dx.doi.org/10.1053/j.gastro.2015.02.055
14. Q.Z.Pan, Q.J.Wang, J.Q.Dan, K.Pan, Y.Q.Li, Y.J.Zhang, J.J.Zhao, D.S.Weng, Y.Tang, L.X.Huang et al. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Sci Rep 2015; 5:9202; PMID:25776856; http://dx.doi.org/10.1038/srep09202
15. L.Tao, G.Huang, S.Shi, L.Chen. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol 2014; 31:777; PMID:24271420; http://dx.doi.org/10.1007/s12032-013-0777-3
16. H.Shi, X.Qi, B.Ma, Y.Cao, L.Wang, L.Sun, H.Niu. The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies. Chin J Cancer Res 2015; 27:128-37; PMID:25937774; http://dx.doi.org/10.3978/j.issn.1000-9604.2014.12.15
17. Y.Iwai, M.Ishida, Y.Tanaka, T.Okazaki, T.Honjo, N.Minato. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7; PMID:12218188; http://dx.doi.org/10.1073/pnas.192461099
18. A.T.Parsa, J.S.Waldron, A.Panner, C.A.Crane, I.F.Parney, J.J.Barry, K.E.Cachola, J.C.Murray, T.Tihan, M.C.Jensen et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84-8; PMID:17159987; http://dx.doi.org/10.1038/nm1517
19. D.M.Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
20. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.A.Gordon, K.Reed et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
21. T.Powles, J.P.Eder, G.D.Fine, F.S.Braiteh, Y.Loriot, C.Cruz, J.Bellmunt, H.A.Burris, D.P.Petrylak, S.L.Teng et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62; PMID:25428503; http://dx.doi.org/10.1038/nature13904
22. M.Postow, J.Taube, R.Anders, C.Taylor, J.Wolchok. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. J Transl Med 2014; 12:O8; http://dx.doi.org/10.1186/1479-5876-12-S1-O8
23. E.B.Garon, N.A.Rizvi, R.Hui, N.Leighl, A.S.Balmanoukian, J.P.Eder, A.Patnaik, C.Aggarwal, M.Gubens, L.Horn et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
24. J.M.Taube, R.A.Anders, G.D.Young, H.Xu, R.Sharma, T.L.McMiller, S.Chen, A.P.Klein, D.M.Pardoll, S.L.Topalian et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127-37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
25. R.S.Herbst, J.C.Soria, M.Kowanetz, G.D.Fine, O.Hamid, M.S.Gordon, J.A.Sosman, D.F.McDermott, J.D.Powderly, S.N.Gettinger et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
26. T.Takayama, T.Sekine, M.Makuuchi, S.Yamasaki, T.Kosuge, J.Yamamoto, K.Shimada, M.Sakamoto, S.Hirohashi, Y.Ohashi et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial. Lancet 2000; 356:802-807; PMID:11022927; http://dx.doi.org/10.1016/S0140-6736(00)02654-4
27. J.Cui, N.Wang, H.Zhao, H.Jin, G.Wang, C.Niu, H.Terunuma, H.He, W.Li. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.Int J Cancer 2014; 134:342-51; PMID:23825037; http://dx.doi.org/10.1002/ijc.28372
28. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10:5094-5100; PMID:15297412; http://dx.doi.org/10.1158/1078-0432.CCR-04-0428
29. R.Karim, E.S.Jordanova, S.J.Piersma, G.G.Kenter, L.Chen, J.M.Boer, C.J.Melief, S.H.van der Burg Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009; 15:6341-7; PMID:19825956; http://dx.doi.org/10.1158/1078-0432.CCR-09-1652
30. R.Hino, K.Kabashima, Y.Kato, H.Yagi, M.Nakamura, T.Honjo, T.Okazaki, Y.Tokura Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899
31. Y.Ohigashi, M.Sho, Y.Yamada, Y.Tsurui, K.Hamada, N.Ikeda, T.Mizuno, R.Yoriki, H.Kashizuka, K.Yane et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11:2947-53; PMID:15837746; http://dx.doi.org/10.1158/1078-0432.CCR-04-1469
32. H.Ghebeh, S.Mohammed, A.Al-Omair, A.Qattan, C.Lehe, G.Al-Qudaihi, N.Elkum, M.Alshabanah, S.Bin Amer, A.Tulbah et al.The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma:correlation with important high-risk prognostic factors. Neoplasia 2006; 8:190-8; PMID:16611412; http://dx.doi.org/10.1593/neo.05733
33. Q.Gao, X.Y.Wang, S.J.Qiu, I.Yamato, M.Sho, Y.Nakajima, J.Zhou, B.Z.Li, Y.H.Shi, Y.S.Xiao et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15:971-9; PMID:19188168; http://dx.doi.org/10.1158/1078-0432.CCR-08-1608
34. Y.Umemoto, S.Okano, Y.Matsumoto, H.Nakagawara, R.Matono, S.Yoshiya, Y.Yamashita, T.Yoshizumi, T.Ikegami, Y.Soejima et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015; 50:65-75; PMID:24509608; http://dx.doi.org/10.1007/s00535-014-0933-3
35. V.Hernandez-Gea, S.Toffanin, S.L.Friedman, J.M.Llovet. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144:512-27; PMID:23313965; http://dx.doi.org/10.1053/j.gastro.2013.01.002
36. H.Ungefroren, S.Sebens, D.Seidl, H.Lehnert, R.Hass. Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011; 9:18; PMID:21914164; http://dx.doi.org/10.1186/1478-811X-9-18
37. O.V.Makarova-Rusher, J.Medina-Echeverz, A.G.Duffy, T.F.Greten. The yin and yang of evasion and immune activation in HCC. J Hepatol 2015; 62:1420-1429; PMID:25733155; http://dx.doi.org/10.1016/j.jhep.2015.02.038
38. D.M.Kuang, Q.Zhao, C.Peng, J.Xu, J.P.Zhang, C.Wu, L.Zheng. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206:1327-37; PMID:19451266; http://dx.doi.org/10.1084/jem.20082173
39. T.Flecken, N.Schmidt, H.C.Spangenberg, R.Thimme. Hepatocellular carcinoma–from immunobiology to immunotherapy. Z Gastroenterol 2012; 50:47-56; PMID:22222798; http://dx.doi.org/10.1055/s-0031-1282002
40. A.Pievani, G.Borleri, D.Pende, L.Moretta, A.Rambaldi, J.Golay, M.Introna. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011; 118:3301-10; PMID:21821703; http://dx.doi.org/10.1182/blood-2011-02-336321
41. R.R.Ji, S.D.Chasalow, L.Wang, O.Hamid, H.Schmidt, J.Cogswell, S.Alaparthy, D.Berman, M.Jure-Kunkel, N.O.Siemers et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61:1019-31; PMID:22146893; http://dx.doi.org/10.1007/s00262-011-1172-6
42. T.F.Gajewski, J.Louahed, V.G.Brichard. Gene signature in melanoma associated with clinical activity:a potential clue to unlock cancer immunotherapy. Cancer J 2010; 16:399-403; PMID:20693853; http://dx.doi.org/10.1097/PPO.0b013e3181eacbd8
43. D.Sprengers, R.G.van der Molen, J.G.Kusters, R.A.De Man, H.G.Niesters, S.W.Schalm, H.L.Janssen. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. J Hepatol 2006; 45:182-9; PMID:16516331; http://dx.doi.org/10.1016/j.jhep.2005.12.022
44. D.Sprengers, R.G.van der Molen, J.G.Kusters, B.Hansen, H.G.Niesters, S.W.Schalm, H.L.Janssen. Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B. J Med Virol 2006; 78:561-8; PMID:16555293; http://dx.doi.org/10.1002/jmv.20576
45. Y.Guo, W.Han. Cytokine-induced killer (CIK) cells:from basic research to clinical translation. Chin J Cancer 2015; 34:99-107; PMID:25962508; http://dx.doi.org/10.1186/s40880-015-0002-1
46. T.Bald, J.Landsberg, D.Lopez-Ramos, M.Renn, N.Glodde, P.Jansen, E.Gaffal, J.Steitz, R.Tolba, U.Kalinke et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 2014; 4:674-87; PMID:24589924; http://dx.doi.org/10.1158/2159-8290.CD-13-0458
47. P.C.Tumeh, C.L.Harview, J.H.Yearley, I.P.Shintaku, E.J.Taylor, L.Robert, B.Chmielowski, M.Spasic, G.Henry, V.Ciobanu et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954
48. K.Pan, X.X.Guan, Y.Q.Li, J.J.Zhao, J.J.Li, H.J.Qiu, D.S.Weng, Q.J.Wang, Q.Liu, L.X.Huang et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res 2014; 20:3003-11; PMID:24668644; http://dx.doi.org/10.1158/1078-0432.CCR-14-0082